Dr. Jyothis George MBBS PhD FRCP FACE

Chief Medical Officer | Developing medicines for obesity, diabetes, cardiovascular disease and beyond | New here on X!

[Dr. Jyothis George MBBS PhD FRCP FACE @drjtgeorge]

Excited to join X! 😀

Even more excited with my #newjob- great potential to deliver transformative medicines for patients by dampening 'bad inflammation' ❤️‍🔥via #nlrp3 #inflammasome inhibition!!

https://t.co/z0PIXp7GBk

[Rezera @RezeraInc]

A majority of patients with #PeripheralArteryDisease (PAD) carry elevated residual inflammatory risk, even on medication. Later-stage PAD patients can have up to a four-fold increase in cardiovascular death.

https://t.co/cckg8JpA45

#PADAwarenessMonth

[Rezera @RezeraInc]

We are excited to announce the upcoming launch of our REVEAL-PAD study to investigate the role of inflammation in #PAD and to identify patients who may be eligible for our planned Phase 3 trial of ruvonoflast in PAD.

Read the full press release: https://t.co/UQ5LHbvpj7

[Rezera @RezeraInc]

We are thrilled to report positive topline results from RESOLVE-1, our Phase 2 trial of ruvonoflast.

Ruvonoflast met the primary inflammation endpoint, with a statistically meaningful reduction in hsCRP at week 24 versus placebo.

https://t.co/Y1OgSLeDLc

#ClinicalTrials

[Rezera @RezeraInc]

Presented today at #EASCongress2026 and concurrently published in @JACC Journals: ruvonoflast showed a robust and sustained 82% reduction in hsCRP together with improvements in cardiometabolic biomarkers.

PR: https://t.co/PhZzGyZNVo

Publication: https://t.co/HsCPQgUgfL

[Subodh Verma @SubodhVermaMD]

Ple as sure to host Dr Jyothis George today. Great friend and leader.

[Rezera @RezeraInc]

Our CMO, @drjtgeorge, joins Leading Beyond the Lab to discuss:

✅ Future of metabolic & inflammatory disease treatment
✅ Leadership in high-stakes biotech
✅ Role of strategic investors

Search “Leading Beyond the Lab Jyothis George” on your favorite podcast platform

[JACC Journals @JACCJournals]

Beyond LDL: Residual inflammatory risk drives recurrent events post-AMI. Time to prioritize inflammation as a treatment target. https://t.co/9ASEvnyRGc

#cvAMI #Inflammation #JACC #cvLipids @DFCapodanno

[Harlan Krumholz @hmkyale]

This is an extraordinary report from @IHME_UW and published in @JACCJournals; it demonstrates that cardiovascular disease is a global scourge. And we are failing to leverage what we know to save lives. https://t.co/fJuiRnJjGn